Mostrar el registro sencillo del ítem

Artículo

dc.creatorVallejo Vaz, Antonio Javieres
dc.creatorLawrence A. Leiteres
dc.creatorStefano del Pratoes
dc.creatorMarja-Riitta Taskinenes
dc.creatorDirk Müller-Wielandes
dc.creatorMaja Bujas-Bobanovices
dc.creatorAlexia Letiercees
dc.creatorJonas Mandeles
dc.creatorRita Samueles
dc.creatorKausik K. Rayes
dc.date.accessioned2023-07-18T11:24:11Z
dc.date.available2023-07-18T11:24:11Z
dc.date.issued2020
dc.identifier.citationVallejo Vaz, A.J., Lawrence A. Leiter, , Stefano del Prato, , Marja-Riitta Taskinen, , Dirk Müller-Wieland, , Maja Bujas-Bobanovic, ,...,Kausik K. Ray, (2020). Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 27 (15), 1663-1674. https://doi.org/10.1177/2047487320905185.
dc.identifier.issn2047-4873es
dc.identifier.issn2047-4881es
dc.identifier.urihttps://hdl.handle.net/11441/148044
dc.description.abstractAims: Guidelines recommend targeting non-high-density lipoprotein cholesterol to reduce cardiovascular risk. We assessed the impact of baseline triglycerides on non-high-density lipoprotein cholesterol goal attainment in 10 phase 3 trials with alirocumab versus control (n = 4983). Methods: Trials were grouped into four pools based on alirocumab dose (75-150 mg every 2 weeks), control (placebo/ezetimibe) and statin use. Baseline triglyceride quintiles were built within each pool. Non-high-density lipoprotein cholesterol goal attainment (very high risk: <100 mg/dl; moderate/high risk: <130 mg/dl), low-density lipoprotein cholesterol goal attainment (very high risk: <70 mg/dl; moderate/high risk: <100 mg/dl) and changes from baseline in lipid parameters were assessed at Week 24 among baseline triglyceride quintiles. Results: Higher baseline triglycerides were associated with a worse cardiovascular risk profile. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol increased with higher triglycerides, but the magnitude in non-high-density lipoprotein cholesterol was three- to four-fold higher compared with the increase in low-density lipoprotein cholesterol. Non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol percentage reductions from baseline with alirocumab were similar regardless of baseline triglycerides. A greater proportion of alirocumab-treated patients attained non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol goals compared with placebo or ezetimibe. Unlike low-density lipoprotein cholesterol goal attainment, non-high-density lipoprotein cholesterol goal attainment significantly declined with increasing baseline triglycerides (p < 0.05 for trend tests). A single standard deviation increase in baseline log(triglycerides) was significantly associated with lower odds ratios of attaining non-high-density lipoprotein cholesterol goals in the different pools and treatment (alirocumab/placebo/ezetimibe) groups, unlike low-density lipoprotein cholesterol goal attainment. Conclusion: Individuals with increased triglycerides have higher non-high-density lipoprotein cholesterol levels and lower rates of non-high-density lipoprotein cholesterol goal attainment (unlike low-density lipoprotein cholesterol goal attainment). Alirocumab improves non-high-density lipoprotein cholesterol goal attainment in this population. These results highlight the impact of triglycerides on non-high-density lipoprotein cholesterol and the need for novel therapies targeting triglyceride-related pathways.es
dc.formatapplication/pdfes
dc.format.extent12 pág.es
dc.language.isoenges
dc.publisherOxford University Presses
dc.relation.ispartofEuropean Journal of Preventive Cardiology, 27 (15), 1663-1674.
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectAlirocumabes
dc.subjectGoal attainmentes
dc.subjectLow-density lipoprotein cholesteroles
dc.subjectNon-high-density lipoprotein cholesteroles
dc.subjectProprotein convertase subtilisin/kexin type 9es
dc.subjectTriglycerideses
dc.titleTriglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumabes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://academic.oup.com/eurjpc/article/27/15/1663/5950574es
dc.identifier.doi10.1177/2047487320905185es
dc.journaltitleEuropean Journal of Preventive Cardiologyes
dc.publication.volumen27es
dc.publication.issue15es
dc.publication.initialPage1663es
dc.publication.endPage1674es
dc.contributor.funderRegeneron Pharmaceuticals, Inc.es
dc.contributor.funderSanofies

FicherosTamañoFormatoVerDescripción
Triglyceride concentrations and ...830.4KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución-NoComercial 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución-NoComercial 4.0 Internacional